| Application no. and date | 22187007.4 (espacenet) (Federated) (European Patent Register), 20091221 | | Patent/reg. no. and date | DK/EP 4098256, 20250226 | | Publication date | 20221207 | | Priority no. and date | US 139672 P, 20081222, US 218530 P, 20090619, US 246715 P, 20090929 | | EP pub. no. and date |
EP 4098256 20221207 | | Effective date | | | Applicant/owner | Novartis AG, Lichtstrasse 35
4056 Basel, CH | | Applicant ref. no. | P028603EPDK1 | | Inventor | SCHMOUDER, Robert,
East Hanover, US,
DUMORTIER, Thomas,
Basel, CH,
DAVID, Olivier,
Basel, CH,
LOOBY, Michael,
Basel, CH | | Representative | CHAS. HUDE A/S, Langebrogade 3B, 1411 København K, DK | | Opponent | | | IPC Class | A61K 31/135 (2006.01) , A61K 31/137 (2006.01) , A61K 31/138 (2006.01) , A61K 31/661 (2006.01) , A61P 37/00 (2006.01) , A61P 37/06 (2006.01) | | Title | DOSERINGSREGIME FOR EN S1P-RECEPTORAGONIST | | Int. application no. | | | Int. publication no. | | | Related patent (certificate) | CA 2025 00015 | | Status | Rettet DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
